Fennec Pharmaceuticals (FENC) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Unity Software stock soars 22% on strong Q3 beat, robust guidance
Tweet
Share
E-mailGet Alerts FENC Hot Sheet
Join SI Premium – FREE
Fennec Pharmaceuticals (NASDAQ: FENC) reported Q4 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.92 million versus the consensus estimate of $7.88 million.
For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Parker-Hannifin (PH) Tops Q1 EPS by 69c ; Offers Guidance
- MACOM Technology Solutions (MTSI) Tops Q4 EPS by 9c ; Offers Guidance
- Holley Inc. (HLLY) Misses Q3 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
